Jaguar Health, Inc.
JAGX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for JAGX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · JAGX
Jaguar Health, Inc. (JAGX) is a commercial-stage pharmaceuticals company focused on developing plant-based, sustainably derived prescription medicines for human and animal health, with its approved product Mytesi for HIV-associated diarrhea.
Key risk: Going concern uncertainty
BioSniper Score
Based on 5 of 6 signals
Market Cap
$4.2M
Cash Runway
5.5 moLead Asset
canalevia-ca1 (Approved)
Next Catalyst
Patent_Expiry · Oct 31, 2031Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 1 catalyst for Jaguar Health, Inc..
Jaguar Health, Inc. (JAGX) is a commercial-stage pharmaceuticals company focused on developing plant-based, sustainably derived prescription medicines for human and animal health, with its approved product Mytesi for HIV-associated diarrhea.
- Jaguar Health is a commercial-stage company with two reportable segments: animal health and human health [sec_mda · as of 2026-05-20].
- The company's approved product Mytesi is indicated for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy [sec_mda · as of 2026-05-20].
- As of 2026-06-30, Jaguar Health reported cash & equivalents of $6.6M, total revenue of $1.2M, and total debt of $15.6M [sec].
- The company is actively pursuing development of its intestinal failure program and a pipeline candidate for Microvillus Inclusion Disease (MVID) [sec_mda · as of 2026-08-19].
What works
- Jaguar Health has a commercially approved product (Mytesi) generating revenue, providing a foundation for ongoing operations [sec_mda · as of 2026-05-20].
- The company has a pipeline targeting intestinal failure and MVID, with potential for non-dilutive funding from licensee partners [sec · filed 2026-06-25].
- Canalevia-CA2, a product candidate for animal health, has concluded clinical testing and is awaiting FDA approval, which could expand the commercial portfolio [sec_mda · as of 2026-08-19].
What to weigh
- Jaguar Health has a history of net losses and expects to incur additional losses in the near term due to significant development expenses [sec_mda · as of 2026-05-20].
- The company faces substantial doubt about its ability to continue as a going concern, requiring additional capital to fund operations [sec_mda · as of 2026-05-20].
- Total debt of $15.6M as of 2026-06-30 significantly exceeds cash & equivalents of $6.6M, indicating financial leverage risk [sec].
- Development costs and timelines remain uncertain due to regulatory and clinical trial complexities, which could delay or increase expenses for pipeline programs [sec_mda · as of 2026-08-19].
From the filings
Quoted directly from source documents.
Jaguar Health is a commercial-stage company with two reportable segments.
“The Company has two reportable segments: animal health and human health.”
SEC MD&A · May 20, 2026
Mytesi is approved for HIV-associated diarrhea.
“Mytesi, which is approved for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.”
SEC MD&A · May 20, 2026
The company expects to incur additional losses.
“We expect to incur additional losses in the near-term future due to significant expenses incurred rel”
SEC MD&A · May 20, 2026
Canalevia-CA2 is awaiting FDA approval.
“clinical testing for Canalevia CA2 concluded on June 30, 2026, and the product is currently awaiting FDA approval.”
SEC MD&A · August 19, 2026
Catalyst timeline
- 2031-10-31 · Patent_Expiry · MYTESI — Patent/Exclusivity Expiry: MYTESI — The patent or exclusivity for Mytesi is set to expire on this date, which could open the product to generic competition.
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — Substantial doubt about ability to continue as a going concern for one year from issuance of financial statements [sec_mda · as of 2026-05-20].
- High debt vs. cash — Total debt of $15.6M exceeds cash & equivalents of $6.6M as of 2026-06-30, creating liquidity pressure [sec].
- Development cost uncertainty — Duration and completion costs of development activities are uncertain due to regulatory and clinical trial complexities [sec_mda · as of 2026-08-19].
- Dependence on partnerships — Failure to generate upfront fees from licensing partnerships would negatively affect the operating plan [sec_mda · as of 2026-08-19].
What to watch
- FDA decision on Canalevia-CA2 for animal health, which could add a new revenue stream [sec_mda · as of 2026-08-19].
- Progress of the intestinal failure and MVID pipeline programs, including potential clinical milestones [sec · filed 2026-06-25].
- Ability to secure non-dilutive funding or licensing partnerships to support pipeline development [sec_mda · as of 2026-08-19].
- Changes in cash runway and debt levels, as the company may need to raise additional capital [sec_mda · as of 2026-05-20].
Sources: SEC filings · SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run Jaguar Health, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Jaguar Health, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
5.5 months
OCF -$5M
Lead: Approved
4 candidates
1 upcoming, next in ~1888d
No insider transactions in the last 180 days
Runway
Catalysts
Pipeline
Financials
Short Interest
as of Apr 30, 2026- % of float
- 4.6%
- Days to cover
- 1.2
- Shares short
- 17,139
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
JAGX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Jaguar Health, Inc.?
Jaguar Health, Inc. (JAGX) is a commercial-stage pharmaceuticals company focused on developing plant-based, sustainably derived prescription medicines for human and animal health, with its approved product Mytesi for HIV-associated diarrhea.
What is Jaguar Health, Inc.'s lead drug candidate?
Jaguar Health, Inc.'s most advanced tracked candidate is canalevia-ca1 (Approved) for chemotherapy-induced diarrhea (CID) in dogs.
What is Jaguar Health, Inc.'s next catalyst?
Jaguar Health, Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: MYTESI" — expected October 31, 2031.
Who is the CEO of Jaguar Health, Inc.?
Ms. Lisa A. Conte is the chief executive officer of Jaguar Health, Inc. (JAGX).
Where is Jaguar Health, Inc. headquartered?
Jaguar Health, Inc. (JAGX) is headquartered in San Francisco, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.